Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24th In January, Acceleron reported that the PULSAR Phase 2 trial in patients ...

For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality companies can see their share prices grow by huge amounts. For example, the Acceleron ...

Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock performs well, when investors win, they can win big. Just think about the savvy ...

The small pharma company had disappointing results from its second phase clinical trials. Here’s why it’s too soon to throw in the towel. The drug showed initial promise for FSHD patients after it ...

Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular ...

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his company was already in talks for its ...

Acceleron's shares skyrocketed last month after its experimental PAH drug hit the mark in a midstage trial. PAH is a rare but serious disorder characterized by abnormally high blood pressure in the ...

Acceleron Pharma ($XLRN) is in Phase III testing for its lead candidate that’s partnered with Celgene ($CELG). Now, it’s brought in a top commercial executive ...

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-oncology megablockbuster Keytruda, but ...

(Reuters) -Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring ...

Drug development is a risky endeavor. So when a small-cap company with a promising pipeline brings in a deep-pocketed partner to front development and commercialization expenses, then announces its ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...